BioSpace News Archive

Genetown

Boston Scientific Announces Upcoming November 2022 Conference Schedule

On November 15, 2022, Dan Brennan, executive vice president and chief financial officer, and Lauren Tengler, vice president, Investor Relations, will participate in a 30-minute question-and-answer session with the host analyst at the 2022 Stifel Healthcare Conference.

November 1, 2022
·
1 min read
Biological Data Visualization Market Size Will Attain USD 2.3 BN by 2030

The Global Biological Data Visualization Market Size accounted for USD 589.7 million in 2021 and is estimated to achieve a market size of USD 2.3 Billion by 2030 growing at a CAGR of xx% from 2022 to 2030.

November 1, 2022
·
12 min read
Business

Daniel Cloutier, a Veteran Sales Executive, Joins Brain Scientific as Chief Revenue Officer

Brain Scientific announces that Daniel Cloutier is joining the company as its chief revenue officer in a move that will help propel the company forward on its mission to revolutionize the medical industry.

November 1, 2022
·
4 min read
Biotech Beach

MedCrypt Raises $25M Series B for Continued Growth and Innovation in Medical Device Cybersecurity

MedCrypt, Inc., the proactive cybersecurity solution provider for medical devices, today announced its $25M Series B funding round.

November 1, 2022
·
3 min read
Research links TNF biologics use with risk of multiple sclerosis

New research from Arthritis Research Canada has shown a link between anti-TNFα biologics and multiple sclerosis.

November 1, 2022
·
3 min read
Closing Chronic Wounds with Collagen Powder: University of Michigan case study demonstrates the efficacy of ColActive Plus Powder in resolving non-healing wounds

Covalon Technologies Ltd., an advanced medical technologies company, announced that its newest advanced wound care product, ColActive Plus Powder, was showcased in a case study presentation at the Symposium on Advanced Wound Care, from October 13 to 16, 2022 in Las Vegas.

November 1, 2022
·
5 min read
Business

Revolution Medicines to Report Financial Results for Third Quarter 2022 After Market Close on November 7, 2022

Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the third quarter 2022 on Monday, November 7, 2022, after market close.

November 1, 2022
·
1 min read
Genetown

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - November 01, 2022

Paratek Pharmaceuticals, Inc. announced that on October 31, 2022, the Company granted stock options to four new employees of the Company.

November 1, 2022
·
2 min read
Business

Occlutech Announces New Member to the Executive Management Team by Appointing Chief Medical Officer

Occlutech Holding AG, one of the world’s leading providers of minimally invasive structural heart disease devices, has appointed Jozef Bartunek, MD, PhD, as new Chief Medical Officer, thus expanding its Executive Management Team.

November 1, 2022
·
3 min read
Business

Memo Therapeutics AG and Ono Pharmaceutical Enter Antibody Discovery Partnership for Immuno-oncology Targets

Memo Therapeutics AG, an innovator in the field of antibody discovery and development, announced the signing of a research and development collaboration agreement with Ono Pharmaceutical Co. Ltd.

November 1, 2022
·
2 min read